No Data
Yabao Pharmaceutical Group (600351.SH): has accumulated a buyback of 0.75% of its shares.
On December 2, according to Gelonghui, Yabao Pharmaceutical Group (600351.SH) announced that as of November 30, 2024, the company has repurchased a total of 5,419,097 shares through centralized bidding, accounting for 0.75% of the company's total share capital. The highest fill price for the repurchase was 6.56 yuan/share, the lowest fill price was 5.87 yuan/share, and the total amount paid was 33,948,400.49 yuan (excluding transaction fees).
Yabao Pharmaceutical Group Gets Registration Certificate for Oral Solution
Yabao pharmaceutical group (600351.SH): The oral solution of ambroxol has obtained the pharmaceutical registration certificate.
On November 21, Glonghui reported that Yabao Pharmaceutical Group (600351.SH) announced that its wholly-owned subsidiary Yabao Pharmaceutical Sichuan Co., Ltd. has received the Drug Registration Certificate for Ambroxol and Clenbuterol Oral Solution issued by the National Medical Products Administration (certificate number: 2024S02777). Ambroxol and Clenbuterol Oral Solution is a compound preparation mainly consisting of Ambroxol hydrochloride and Clenbuterol hydrochloride, primarily used to relieve symptoms of respiratory diseases. It is suitable for treating cough, viscous phlegm, difficulty in sputum discharge, and wheezing caused by acute and chronic respiratory diseases (such as acute and chronic bronchitis, pulmonary emphysema, etc.).
yabao pharmaceutical group's two children's medicines revenue increased year-on-year, hydrochloride betahistine injection has not stopped the decline in revenue|direct hit earnings conference
yabao pharmaceutical group stated at the earnings conference that in the first three quarters of this year, the company's pediatric products revenue increased year-on-year. The company's secretary stated that while the revenue of levocetirizine hydrochloride injection decreased, the sales volume increased, and predicted that the 'income decline in the category will continue to narrow within the year'. yabao pharmaceutical group also provided explanations on the company's research pipeline progress, share buybacks, and other situations.
Yabao Pharmaceutical Group Co., Ltd. Report for the Third Quarter of 2024 (Revised Edition)
Yabao Pharmaceutical Group Co., Ltd. 2024 Third Quarter Report Correction Notice
The Market Doesn't Like What It Sees From Yabao Pharmaceutical Group Co., Ltd's (SHSE:600351) Earnings Yet As Shares Tumble 27%
